EUVIMEDEUVIMED entdecken
Crossref

Rational Design of Single‐Atom Nanozymes for Combination Cancer Immunotherapy

Hanchao Lin, Yonghui Gao, Le Zhu, Yu Guo, Lumin Zhang, Jiali Xie, Dongqin Yang, Jing Liu, Qiongzhu Dong, Zhiling Zhu

Advanced Functional Materials · 2025-03 · 35 (10)

DOI: 10.1002/adfm.202416563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 21.01.2025. Verfasst von Hanchao Lin und 9 weiteren Autor:innen. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Key Research and Development Program of China, School of Medicine, Shanghai Jiao Tong University, Taishan Scholar Foundation of Shandong Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remodeling of the tumor immune microenvironment and enhancement of antitumor immune responses are necessary to overcome immunotherapy resistance in tumors. However, tumor heterogeneity and complexity of immune evasion mechanisms pose significant therapeutic challenges. Nanozymes exhibit enzyme‐like characteristics and unique nanomaterial properties, showing potential for tumor therapy. However, design of effective nanozymes remains complex, inefficient, and functionally limited. Therefore, in this study, a novel strategy combining rationally designed single‐atom nanozymes (SAzymes) with immune checkpoint blockade (ICB) therapy is established. Molybdenum SAzymes supported on graphitic carbon nitride (Mo SAs) are constructed using 25 transition metal candidates from the 4th to 6th periods based on high‐throughput calculations and optimal piezoelectric‐enhanced multienzyme‐like activities. Upon activation by ultrasound, Mo SAs exerted potent therapeutic effects against ICB‐resistant tumors and remodeled the tumor immune microenvironment by inducing tumor immunogenic cell death, alleviating tumor hypoxia, and modulating chemokine expression in tumors. Combination of Mo SAs with anti‐programmed death protein‐1 antibodies further enhanced their antitumor efficacy, highlighting their potential to treat ICB‐resistant tumors.

Förderung

  • National Key Research and Development Program of China
  • School of Medicine, Shanghai Jiao Tong University
  • Taishan Scholar Foundation of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Lin, H., Gao, Y., Zhu, L., Guo, Y., Zhang, L., Xie, J., Yang, D., Liu, J., Dong, Q., & Zhu, Z. (2025). Rational Design of Single‐Atom Nanozymes for Combination Cancer Immunotherapy. Advanced Functional Materials, 35(10). https://doi.org/10.1002/adfm.202416563

Vancouver

Lin H, Gao Y, Zhu L, Guo Y, Zhang L, Xie J, et al. Rational Design of Single‐Atom Nanozymes for Combination Cancer Immunotherapy. Advanced Functional Materials. 2025;35(10). doi:10.1002/adfm.202416563

BibTeX
@article{Lin2025,
  author = {Lin, Hanchao and Gao, Yonghui and Zhu, Le and Guo, Yu and Zhang, Lumin and Xie, Jiali and Yang, Dongqin and Liu, Jing and Dong, Qiongzhu and Zhu, Zhiling},
  title = {Rational Design of Single‐Atom Nanozymes for Combination Cancer Immunotherapy},
  journal = {Advanced Functional Materials},
  year = {2025},
  volume = {35},
  number = {10},
  doi = {10.1002/adfm.202416563}
}
Kostenlos starten →